Background. The outcome of endovascular therapy can be influenced by a number of factors, either demographic, biochemical, angiographic or procedural. Knowledge about these factors may help in the individualization of therapeutic methods, surveillance intensity, and should, ultimately, improve intervention efficacy.Objectives. The aim of this study was to estimate the effect of clinical and biochemical factors on the late outcome of lower limb artery stenting.Material and methods. The medical documentation of 91 patients with at least a 1 year follow-up after the stenting of a lower limb artery was retrospectively evaluated. Uni-and multivariate analyses were performed.Results. Primary patency within an approximately 1.5-year follow-up amounted to 68.2%. The probability of freedom from target lesion revascularization was significantly greater in patients with dyslipidemia. According to the Cox proportional-hazards analysis, the risk of target extremity revascularization was significantly affected by the following (hazard ratio [HR], 95% confidence interval): Age (0.93, 0.88-0.99); dyslipidemia at inclusion (0.046, 0.01-0.23); LDL blood concentration (1.02; 1.01-1.04); hematocrit (1.2, 1.02-1.42); mean platelet volume (0.66, 0.44-0.99); INR (1.58, 1.13-2.21); and aPTT (1.18, 1.07-1.3).Conclusions. Endovascular treatment with stenting in patients with atherosclerotic peripheral arterial disease is effective, but the risk of primary patency loss was affected by the presence of dyslipidemia, age, and blood coagulation parameters. The effect of dyslipidemia on stent failure occurrence should be evaluated in further studies.
Introduction. Critical limb ischaemia (CLI) is an advanced phase of chronic lower extremity ischaemia linked to increased mortality
IntroductionAbout 20–30% of the population have peripheral artery disease. Many of them require intervention, with a percutaneous procedure currently being the first choice. However, the outcomes of these interventions need regular evaluation due to continuous progress in endovascular techniques and the devices used.AimThe aim of this study was to analyze procedural factors influencing the outcome of endovascular intervention in patients stented for the first time due to lower extremity atherosclerosis.Material and methodsThe medical documentation of 91 patients with at least 1 year of follow-up after stenting of a lower limb artery was retrospectively evaluated. Uni- and multivariate analyses were performed.ResultsThe mean observation time was 544.4 ±502.9 days. The primary patency of a stent after such a follow-up was 68.1%. Cox proportional hazard analysis revealed that the risk of target lesion revascularization was affected by the following (hazard risk, 95% confidence interval): the number of vascular segments with significant lesions (13.14, 2.28–75.8); critical limb ischemia (5.68, 1.23–26.2); localization of the target lesion in an aorto-iliac in comparison with a femoro-popliteal vascular segment (0.37, 0.14–0.7); aorto-iliac lesion class according to the TASC-II consensus (1.96, 1.1–3.8); and claudication distance (1.02, 1.01–1.03).ConclusionsThe common primary patency of a stent implanted into either an aorto-iliac or a femoro-popliteal vascular segment was similar to that found in other reports. The main factors affecting the outcome of the endovascular procedures performed were mainly related to atherosclerosis severity, not to the type of technique or device used.
S u m m a r y O b j e c t i v e s . Leg ischemia is the third leading cause of atherosclerotic cardiovascular morbidity, concerning about 20-30% of the elderly population. Recognition of its risk factors helps in early diagnosis and patient management. The aim of this study was to determine the prevalence of respective atherosclerosis risk factors among patients with peripheral artery disease (PAD) referred for lower limb endovascular revascularization and compare their prevalence with the data obtained in large epidemiological investigations and in patients with atherosclerosis manifestation in coronary and cerebral vascular beds. M a t e r i a l a n d m e t h o d s . Medical documentation for 73 male patients with PAD after a first endovascular intervention was evaluated retrospectively, and the prevalence of atherosclerosis risk factors found was compared with historical control groups from the literature. R e s u l t s . The patients studied presented significantly greater prevalence of a current smoking habit and diabetes mellitus than in the POLSCREEN, WOBASZ and NATPOL PLUS studies, significantly greater prevalence of hypertension than in WOBASZ and NATPOL PLUS, significantly greater prevalence of dyslipidemia than in POLSCREEN and NATPOL PLUS, significantly lower prevalence of BMI ≥ 25 kg/m 2 than in POLSCREEN, and greater than in NATPOL PLUS. In comparison to patients with coronary artery disease (CAD), individuals with PAD had a lower prevalence of hypertension and overweight and/or obesity, but greater occurrence of a current smoking habit and dyslipidemia. C o n c l u s i o n s . Patients with PAD who were qualified for endovascular therapy presented greater prevalence of atherosclerosis risk factors and multisite vascular disease manifestation than various general Polish populations and subjects with CAD, which suggests the need for the improved management of these patients.S t r e s z c z e n i e C e l e . Przewlekłe niedokrwienie kończyn dolnych (PNKD) jest trzecim, co do częstości, schorzeniem sercowonaczyniowym, dotyczącym około 20-30% dorosłej populacji. Określenie czynników ryzyka PNKD jest istotne dla wczesnej diagnozy i właściwego leczenia chorych. Celem pracy było porównanie częstości występowania poszczególnych czynników ryzyka u pacjentów leczonych wewnątrznaczyniowo z powodu PNKD z danymi
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.